Relmada Therapeutics, Inc. (RLMD): Price and Financial Metrics

Relmada Therapeutics, Inc. (RLMD): $2.79

-0.06 (-2.11%)

POWR Rating

Component Grades

Momentum

B

Stability

C

Sentiment

Quality

C

Add RLMD to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#161 of 381

in industry

RLMD Price/Volume Stats

Current price $2.79 52-week high $38.68
Prev. close $2.85 52-week low $1.81
Day low $2.74 Volume 12,020
Day high $2.90 Avg. volume 231,827
50-day MA $2.78 Dividend yield N/A
200-day MA $9.23 Market Cap 83.98M

RLMD Stock Price Chart Interactive Chart >


Relmada Therapeutics, Inc. (RLMD) Company Bio


Relmada Therapeutics, Inc. is a clinical stage, public specialty pharmaceutical company who develops a variety of established drug products. The Company also researches and procures chemical entities with a focus on the treatment of pain.


RLMD Latest News Stream


Event/Time News Detail
Loading, please wait...

RLMD Latest Social Stream


Loading social stream, please wait...

View Full RLMD Social Stream

Latest RLMD News From Around the Web

Below are the latest news stories about RELMADA THERAPEUTICS INC that investors may wish to consider to help them evaluate RLMD as an investment opportunity.

Relmada Therapeutics to Participate in the 2023 Jefferies Global Healthcare Conference

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, Maged Shenouda, Chief Financial Officer, and Cedric O'Gorman, Chief Medical Officer, will participate in the 2023 Jefferies Global Healthcare Conference in one-on-one investor meetings and a fireside chat on Thursday, June 8, 2023, at 3:00pm ET in New York, NY. Please find additional details about the

Yahoo | June 2, 2023

Relmada Therapeutics Insider Ups Holding By 62% During Year \

From what we can see, insiders were net buyers in Relmada Therapeutics, Inc.'s ( NASDAQ:RLMD ) during the past 12...

Yahoo | May 24, 2023

Relmada Therapeutics to Present Data at the American Society of Clinical Psychopharmacology 2023 Annual Meeting

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that clinical data related to REL-1017, the company's lead product candidate, will be presented in-person in two late-breaking poster presentations at the American Society of Clinical Psychopharmacology 2023 Annual Meeting. The conference is being held Tuesday, May 30 – Friday, June 2, 2023, in Miami, FL.

Yahoo | May 24, 2023

Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the first quarter ended March 31, 2023. The Company will host a conference call today, Thursday, May 11, at 4:30 PM Eastern Time/1:30 PM Pacific Time.

Yahoo | May 11, 2023

Relmada Therapeutics to Report First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 11, 2023

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2023 after the market close on Thursday, May 11th, 2023. The company will host a corporate update conference call and live audio webcast at 4:30 p.m. Eastern Time on Thursday, May 11, 2023.

Yahoo | May 8, 2023

Read More 'RLMD' Stories Here

RLMD Price Returns

1-mo -13.35%
3-mo -15.20%
6-mo 28.57%
1-year -84.48%
3-year -94.15%
5-year -52.22%
YTD -20.06%
2022 -84.51%
2021 -29.75%
2020 -17.77%
2019 747.83%
2018 53.33%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!